A critical review of lipid-based nanoparticles for taxane delivery

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 157-175

  Feng, Lan ^a   Mumper, Russell J ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Lipid based; Nanoparticles; Taxane

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALPHA TOCOPHEROL; ANTIHISTAMINIC AGENT; CASTOR OIL; CHOLESTEROL; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DAUOXOME; DOCETAXEL; DOXORUBICIN; EXCIPIENT; LIPID; LIPOSOME; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PEPTIDE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; RICINOMACROGOL; SOLID LIPID NANOPARTICLE; SURFACTANT; TAXANE DERIVATIVE; TOPOTECAN; TRIBUTYRIN; TRIOCTANOIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; BIOCOMPATIBILITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; COLORECTAL CANCER; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG UPTAKE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; HYDROPHOBICITY; LIPID BILAYER; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MICELLE; NANOPHARMACEUTICS; NEUTROPENIA; OVARY CANCER; PATHOLOGICAL ANATOMY; PERIPHERAL NEUROPATHY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 84878226506     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.006     Document Type: Review

References (205)

1. Cortes J.E., Pazdur R. Docetaxel. J. Clin. Oncol. 1995, 13:2643-2655.
2. Hamada H., Ishihara K., Masuoka N., Mikuni K., Nakajima N. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J. Biosci. Bioeng. 2006, 102:369-371.
3. Mathew A.E., Mejillano M.R., Nath J.P., Himes R.H., Stella V.J. Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumor-activity. J. Med. Chem. 1992, 35:145-151.
4. Du W., Hong L., Yao T., Yang X., He Q., Yang B., Hu Y. Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg. Med. Chem. 2007, 15:6323-6330.
5. Ali S.M., Hoemann M.Z., Aube J., Georg G.I., Mitscher L.A., Jayasinghe L.R. Butitaxel analogues: synthesis and structure-activity relationships. J. Med. Chem. 1997, 40:236-241.
6. Zaske L., Perrin M.A., Leveiller F. Docetaxel: solid state characterization by X-ray powder diffraction and thermogravimetry. J. Phys. IV 2001, 11:221-226.
7. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by Taxol. Nature 1979, 277:665-667.
8. Ringel I., Horwitz S.B. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl. Cancer Inst. 1991, 83:288-291.
9. Horwitz S.B. Mechanism of action of Taxol. Trends Pharmacol. Sci. 1992, 13:134-136.
10. Guerittevoegelein F., Guenard D., Lavelle F., Legoff M.T., Mangatal L., Potier P. Relationships between the structure of Taxol analogs and their antimitotic activity. J. Med. Chem. 1991, 34:992-998.
11. Diaz J.F., Andreu J.M. Assembly of purified GDP tubulin into microtubules induced by Taxol and Taxotere - reversibility, ligand stoichiomet, and competition. Biochemistry - US 1993, 32:2747-2755.
12. J. Riou, O. Petitgenet, C. Combeau, et al., Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line, Proc. Am. Assoc. Cancer Res. 35 (1994) 385.
13. Taxol® (Paclitaxel) Injection, Bristol-Myers Squibb, Princeton, 2011.
14. Sonnichsen D.S., Relling M.V. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet. 1994, 27:256-269.
15. Rowinsky E.K., Wright M., Monsarrat B., Donehower R.C. Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. Ann. Oncol. 1994, 5(Suppl. 6):S7-16.
16. Ellis A.G., Crinis N.A., Webster L.K. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother. Pharmacol. 1996, 38:81-87.
17. Sparreboom A., van Zuylen L., Brouwer E., Loos W.J., de Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., Verweij J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999, 59:1454-1457.
18. van Zuylen L., Karlsson M.O., Verweij J., Brouwer E., de Bruijn P., Nooter K., Stoter G., Sparreboom A. Pharmacokinetic modeling of paclitaxel encapsulation in cremophor EL micelles. Cancer Chemother. Pharmacol. 2001, 47:309-318.
19. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., Baker J.R., Van Echo D.A., Von Hoff D.D., Leyland-Jones B. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 1990, 8:1263-1268.
20. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8:1038-1044.
21. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Exp. Opin. Pharmacother. 2006, 7:1041-1053.
22. Loos W.J., Baker S.D., Verweij J., Boonstra J.G., Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin. Pharmacol. Ther. 2003, 74:364-371.
23. Bissery M., Renard A., Andre S., et al. Preclinical pharmacology and toxicology of Taxotere (RP 56976, NSC 628503). Ann. Oncol. 1992, 3:121.
24. A. Renate, M.C. Bissery, G. Montay, et al., Taxotere: antitumor activity and pharmacokinetics in mice, Proc. Am. Assoc. Cancer Res. 32 (1991) 401.
25. Pinguet F., Agustin M.J., Brown P., Soefje S., Needleman R., Sanchez M.N., Sommer U., Tranter B. New formulation Taxotere (R) reduces preparation time and supports the physical stability of the product in infusion bags: data from the RELIUS international observational study. Ejhp. Pract. 2010, 16:40-43.
26. Marupudi N.I., Han J.E., Li K.W., Renard V.M., Tyler B.M., Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Exp. Opin. Drug Saf. 2007, 6:609-621.
27. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997, 48:353-374.
28. Campbell R.B. Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med. Chem. 2006, 6:503-512.
29. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7:653-664.
30. Shubik P. Vascularization of tumors: a review. J. Cancer Res. Clin. Oncol. 1982, 103:211-226.
31. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95:4607-4612.
32. Takakura Y., Mahato R.I., Hashida M. Extravasation of macromolecules. Adv. Drug Deliv. Rev. 1998, 34:93-108.
33. Karakotchian M., Fraser I.S. An ultrastructural study of microvascular inter-endothelial tight junctions in normal endometrium. Micron 2007, 38:632-636.
34. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
35. Leu A.J., Berk D.A., Lymboussaki A., Alitalo K., Jain R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000, 60:4324-4327.
36. Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
37. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
38. Boucher Y., Kirkwood J.M., Opacic D., Desantis M., Jain R.K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991, 51:6691-6694.
39. Sevick E.M., Jain R.K. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res. 1989, 49:3506-3512.
40. Vijayagopal P., Figueroa J.E., Levine E.A. Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. J. Surg. Oncol. 1998, 68:250-254.
41. Pluen A., Boucher Y., Ramanujan S., McKee T.D., Gohongi T., di Tomaso E., Brown E.B., Izumi Y., Campbell R.B., Berk D.A., Jain R.K. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. USA 2001, 98:4628-4633.
42. Chauhan V.P., Lanning R.M., Diop-Frimpong B., Mok W., Brown E.B., Padera T.P., Boucher Y., Jain R.K. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys. J. 2009, 97:330-336.
43. Alexandrakis G., Brown E.B., Tong R.T., McKee T.D., Campbell R.B., Boucher Y., Jain R.K. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat. Med. 2004, 10:203-207.
44. Voskoglou-Nomikos T., Pater J.L., Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 2003, 9:4227-4239.
45. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., Mumper R.J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69:3918-3926.
46. Sharma S.V., Haber D.A., Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 2010, 10:241-253.
47. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans - better than commonly perceived - but they can be improved. Cancer Biol. Ther. 2003, 2:S134-S139.
48. Peterson J.K., Houghton P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 2004, 40:837-844.
49. Takimoto C.H. Why drugs fail: of mice and men revisited. Clin. Cancer Res. 2001, 7:229-230.
50. Suggitt M., Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin. Cancer Res. 2005, 11:971-981.
51. Naito S., von Eschenbach A.C., Fidler I.J. Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. J. Natl. Cancer Inst. 1987, 78:377-385.
52. Morikawa K., Walker S.M., Jessup J.M., Fidler I.J. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res. 1988, 48:1943-1948.
53. Gohji K., Nakajima M., Fabra A., Bucana C.D., von Eschenbach A.C., Tsuruo T., Fidler I.J. Regulation of gelatinase production in metastatic renal cell carcinoma by organ-specific fibroblasts. Jpn. J. Cancer Res. 1994, 85:152-160.
54. Gutman M., Singh R.K., Price J.E., Fan D., Fidler I.J. Accelerated growth of human colon cancer cells in nude mice undergoing liver regeneration. Invasion Metastasis 1994, 14:362-371.
55. Killion J.J., Radinsky R., Fidler I.J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998, 17:279-284.
56. Schuetz J.D., Schuetz E.G. Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes. Cell Growth Differ. 1993, 4:31-40.
57. Mead J.E., Fausto N. Transforming growth factor-alpha may be a physiological regulator of liver-regeneration by means of an autocrine mechanism. Proc. Natl. Acad. Sci. USA 1989, 86:1558-1562.
58. Hoffman R.M. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol. 2002, 3:546-556.
59. El Hilali N., Rubio N., Martinez-Villacampa M., Blanco J. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest. 2002, 82:1563-1571.
60. Kuo T.H., Kubota T., Watanabe M., Furukawa T., Kase S., Tanino H., Saikawa Y., Ishibiki K., Kitajima M., Hoffman R.M. Site-specific chemosensitivity of human small-cell lung-carcinoma growing orthotopically compared to subcutaneously in scid mice - the importance of orthotopic models to obtain relevant drug-evaluation data. Anticancer Res. 1993, 13:627-630.
61. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79:185-188.
62. Cowen S.E., Bibby M.C., Double J.A. Characterization of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol. 1995, 34:357-360.
63. Wilmanns C., Fan D., Obrian C., Radinsky R., Bucana C., Tsan R., Fidler I. Modulation of doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int. J. Oncol. 1993, 3:413-422.
64. Dexter D.L., Diamond M., Creveling J., Chen S.F. Chemotherapy of mammary carcinomas arising in Ras transgenic mice. Invest. New Drug 1993, 11:161-168.
65. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. USA 2000, 97:10173-10178.
66. Bearss D.J., Subler M.A., Hundley J.E., Troyer D.A., Salinas R.A., Windle J.J. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 2000, 19:1114-1122.
67. Simeonova M., Ilarionova M., Ivanova T., Konstantinov C., Todorov D. Nanoparticles as drug carriers for vinblastine. Acute toxicity of vinblastine in a free form and associated to polybutylcyanoacrylate nanoparticles. Acta Physiol. Pharmacol. Bulg. 1991, 17:43-49.
68. Souza L.G., Silva E.J., Martins A.L., Mota M.F., Braga R.C., Lima E.M., Valadares M.C., Taveira S.F., Marreto R.N. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur. J. Pharm. Biopharm. 2011, 79:189-196.
69. Yang S.C., Zhu J.B. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2002, 28:265-274.
70. Lim S.J., Lee M.K., Kim C.K. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J. Control. Release 2004, 100:53-61.
71. Williams J., Lansdown R., Sweitzer R., Romanowski M., LaBell R., Ramaswami R., Unger E. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J. Control. Release 2003, 91:167-172.
72. B. Isacchi, S. Arrigucci, G.L. Marca, M.C. Bergonzi, M.G. Vannucchi, A. Novelli, A.R. Bilia, Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice, J. Liposome Res. (2010).
73. Cole A.J., David A.E., Wang J., Galban C.J., Hill H.L., Yang V.C. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials 2011, 32:2183-2193.
74. Kim C.K., Kim J.Y., Kim J.K., Park J.S., Byun Y. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009, 30:5751-5756.
75. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1:297-315.
76. L.J. Benhabbour, D. Kim, A. Jain, S. Wadhwa, M.C. Parrott, R. Liu, J. Desimone, R.J. Mumper, In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel heptameric Z (EGFR) domain, J. Control. Release (2011).
77. Patel J.D., O'Carra R., Jones J., Woodward J.G., Mumper R.J. Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens. Pharm. Res. 2007, 24:343-352.
78. Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J.G., Nath A., Mumper R.J. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 2004, 22:2631-2640.
79. McConathy W.J., Nair M.P., Paranjape S., Mooberry L., Lacko A.G. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-Cancer Drug 2008, 19:183-188.
80. Straubinger R.M., Balasubramanian S.V. Preparation and characterization of taxane-containing liposomes. Methods Enzymol. 2005, 391:97-117.
81. Sharma A., Straubinger R.M. Novel Taxol formulations: preparation and characterization of Taxol-containing liposomes. Pharm. Res. 1994, 11:889-896.
82. Campbell R.B., Balasubramanian S.V., Straubinger R.M. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J. Pharm. Sci. 2001, 90:1091-1105.
83. Sharma A., Mayhew E., Straubinger R.M. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res. 1993, 53:5877-5881.
84. Zhang J.A., Anyarambhatla G., Ma L., Ugwu S., Xuan T., Sardone T., Ahmad I. Development and characterization of a novel cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 2005, 59:177-187.
85. Balasubramanian S.V., Alderfer J.L., Straubinger R.M. Solvent- and concentration-dependent molecular interactions of Taxol (paclitaxel). J. Pharm. Sci. 1994, 83:1470-1476.
86. Balasubramanian S.V., Straubinger R.M. Taxol-lipid interactions: Taxol-dependent effects on the physical properties of model membranes. Biochemistry - US 1994, 33:8941-8947.
87. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release 2000, 63:19-30.
88. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 2006, 115:243-250.
89. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 1997, 71:103-107.
90. Sharma A., Sharma U.S., Straubinger R.M. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996, 107:265-272.
91. Cabanes A., Briggs K.E., Gokhale P.C., Treat J.A., Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J. Oncol. 1998, 12:1035-1040.
92. Schmitt-Sody M., Strieth S., Krasnici S., Sauer B., Schulze B., Teifel M., Michaelis U., Naujoks K., Dellian M. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 2003, 9:2335-2341.
93. Soepenberg O., Sparreboom A., de Jonge M.J., Planting A.S., de Heus G., Loos W.J., Hartman C.M., Bowden C., Verweij J. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur. J. Cancer 2004, 40:681-688.
94. Arleth L., Ashok B., Onyuksel H., Thiyagarajan P., Jacob J., Hjelm R.P. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 2005, 21:3279-3290.
95. Mu L., Elbayoumi T.A., Torchilin V.P. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int. J. Pharmaceut. 2005, 306:142-149.
96. Vakil R., Kwon G.S. Effect of cholesterol on the release of amphotericin B from PEG-phospholipid micelles. Mol. Pharm. 2008, 5:98-104.
97. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., Onyuksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J. Pharm. Sci. 2004, 93:2476-2487.
98. Lim S.B., Rubinstein I., Onyuksel H. Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles. Int. J. Pharm. 2008, 356:345-350.
99. La S.B., Okano T., Kataoka K. Preparation and characterization of the micelle-forming polymeric drug indomethacin-incorporated poly(ethylene oxide)-poly(beta-benzyl l-aspartate) block copolymer micelles. J. Pharm. Sci. 1996, 85:85-90.
100. Krishnadas A., Rubinstein I., Onyuksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm. Res. 2003, 20:297-302.
101. Onyuksel H., Jeon E., Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009, 274:327-330.
102. Dabholkar R.D., Sawant R.M., Mongayt D.A., Devarajan P.V., Torchilin V.P. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm. 2006, 315:148-157.
103. Sawant R.R., Torchilin V.P. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol. Membr. Biol. 2010, 27:232-246.
104. Lukyanov A.N., Gao Z., Mazzola L., Torchilin V.P. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm. Res. 2002, 19:1424-1429.
105. Anton N., Vandamme T.F. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm. Res. 2011, 28:978-985.
106. Lawrence M.J., Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliver. Rev. 2000, 45:89-121.
107. Solans P.I.C., Nolla J., Azemar N., Garcia-Celma M.J. Nano-emulsions. Curr. Opin. Colloid Interface Sci. 2005, 10:102-110.
108. Tarr B.D., Sambandan T.G., Yalkowsky S.H. A new parenteral emulsion for the administration of Taxol. Pharm. Res. 1987, 4:162-165.
109. Constantinides P.P., Lambert K.J., Tustian A.K., Schneider B., Lalji S., Ma W., Wentzel B., Kessler D., Worah D., Quay S.C. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm. Res. 2000, 17:175-182.
110. Constantinides P.P., Tustian A., Kessler D.R. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev. 2004, 56:1243-1255.
111. Gao J.S.K., Liu K., Liu X.H., He Z.G. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev. Ind. Pharm. 2008, 34:1227-1237.
112. Kan P., Chen Z.B., Lee C.J., Chu I.M. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J. Control. Release 1999, 58:271-278.
113. Tiwari S.B., Amiji M.M. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J. Nanosci. Nanotechnol. 2006, 6:3215-3221.
114. Yin Y.M., Cui F.D., Mu C.F., Choi M.K., Kim J.S., Chung S.J., Shim C.K., Kim D.D. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J. Control. Release 2009, 140:86-94.
115. Maranhao R.C., Garicochea B., Silva E.L., Dorlhiac-Llacer P., Cadena S.M., Coelho I.J., Meneghetti J.C., Pileggi F.J., Chamone D.A. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res. 1994, 54:4660-4666.
116. Rodrigues D.G., Maria D.A., Fernandes D.C., Valduga C.J., Couto R.D., Ibanez O.C., Maranhao R.C. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. 2005, 55:565-576.
117. Dias M.L., Carvalho J.P., Rodrigues D.G., Graziani S.R., Maranhao R.C. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol. 2007, 59:105-111.
118. Pires L., Hegg R., Valduga C., Graziani S., Rodrigues D., Maranhao R.C. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother. Pharmacol. 2009, 63:281-287.
119. Nikanjarn M., Gibbs A.R., Hunt A., Budinger T.F., Forte T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release 2007, 124:163-171.
120. Wissing S.A., Kayser O., Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
121. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
122. Jenning V., Lippacher A., Gohla S.H. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J. Microencapsul. 2002, 19:1-10.
123. Dingler A., Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J. Microencapsul. 2002, 19:11-16.
124. Oyewumi M.O., Mumper R.J. Gadolinium-loaded nanoparticles engineered from microemulsion templates. Drug Dev. Ind. Pharm. 2002, 28:317-328.
125. Chen D.B., Yang T.Z., Lu W.L., Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. (Tokyo) 2001, 49:1444-1447.
126. Lee M.K., Lim S.J., Kim C.K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007, 28:2137-2146.
127. Dong X.W., Mattingly C.A., Tseng M., Cho M., Adams V.R., Mumper R.J. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur. J. Pharm. Biopharm. 2009, 72:9-17.
128. Shenoy V.S., Rajyaguru T.H., Gude R.P., Murthy R.S. Studies on paclitaxel-loaded glyceryl monostearate nanoparticles. J. Microencapsul. 2009, 26:471-478.
129. Cavalli R., Caputo O., Gasco M.R. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 2000, 10:305-309.
130. Shahgaldian P., Da Silva E., Coleman A.W., Rather B., Zaworotko M.J. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int. J. Pharm. 2003, 253:23-38.
131. Westesen K., Bunjes H., Koch M.H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release 1997, 48:223-236.
132. Arica Yegin B., Benoit J.P., Lamprecht A. Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev. Ind. Pharm. 2006, 32:1089-1094.
133. A. Zur Muhlen, C. Schwarz, W. Mehnert, Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism, Eur. J. Pharm. Biopharm. 45 (1998) 149-155.
134. Muhlen A., Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 1998, 53:552.
135. Muller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002, 242:121-128.
136. Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 2008, 348:137-145.
137. Koziara J.M., Oh J.J., Akers W.S., Ferraris S.P., Mumper R.J. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 2005, 22:1821-1828.
138. Wang J.X., Sun X., Zhang Z.R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2002, 54:285-290.
139. Fundaro A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000, 42:337-343.
140. Zara G.P., Cavalli R., Bargoni A., Fundaro A., Vighetto D., Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target. 2002, 10:327-335.
141. Zara G.P., Cavalli R., Fundaro A., Bargoni A., Caputo O., Gasco M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res. 1999, 40:281-286.
142. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 1999, 59:299-307.
143. Harivardhan Reddy L., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.S. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Release 2005, 105:185-198.
144. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 2004, 99:259-269.
145. Landfester K. Polyreactions in miniemulsions. Abstr. Pap. Am. Chem. S 2002, 224:U500.
146. Rollot J.M., Couvreur P., Roblot-Treupel L., Puisieux F. Physicochemical and morphological characterization of polyisobutyl cyanoacrylate nanocapsules. J. Pharm. Sci. 1986, 75:361-364.
147. Scott C., Wu D., Ho C.C., Co C.C. Liquid-core capsules via interfacial polymerization: a free-radical analogy of the nylon rope trick. J. Am. Chem. Soc. 2005, 127:4160-4161.
148. Galindo-Rodriguez S., Allemann E., Fessi H., Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm. Res. 2004, 21:1428-1439.
149. Bartoli M.H., Boitard M., Fessi H., Beriel H., Devissaguet J.P., Picot F., Puisieux F. In vitro and in vivo antitumoral activity of free, and encapsulated Taxol. J. Microencapsul. 1990, 7:191-197.
150. Oh K.S., Lee K.E., Han S.S., Cho S.H., Kim D., Yuk S.H. Formation of core/shell nanoparticles with a lipid core and their application as a drug delivery system. Biomacromolecules 2005, 6:1062-1067.
151. Bae K.H., Lee Y., Park T.G. Oil-encapsulating PEO-PPO-PEO/PEG shell cross-linked nanocapsules for target-specific delivery of paclitaxel. Biomacromolecules 2007, 8:650-656.
152. Zhang Y., Zhu S.Y., Yin L.C., Qian F., Tang C., Yin C.H. Preparation, characterization and biocompatibility of poly(ethylene glycol)-poly(n-butyl cyanoacrylate) nanocapsules with oil core via miniemulsion polymerization. Eur. Polym. J. 2008, 44:1654-1661.
153. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharmaceut. 2009, 379:201-209.
154. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 2002, 19:875-880.
155. Lacoeuille F., Hindre F., Moal F., Roux J., Passirani C., Couturier O., Cales P., Le Jeune J.J., Lamprecht A., Benoit J.P. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int. J. Pharmaceut. 2007, 344:143-149.
156. Garcion E., Lamprecht A., Heurtault B., Paillard A., Aubert-Pouessel A., Denizot B., Menei P., Benoit J.P. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 2006, 5:1710-1722.
157. Peltier S., Oger J.M., Lagarce F., Couet W., Benoit J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 2006, 23:1243-1250.
158. Khalid M.N., Simard P., Hoarau D., Dragomir A., Leroux J.C. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm. Res. 2006, 23:752-758.
159. Skwarczynski M., Hayashi Y., Kiso Y. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49:7253-7269.
160. Stevens P.J., Sekido M., Lee R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 2004, 21:2153-2157.
161. Lundberg B.B., Risovic V., Ramaswamy M., Wasan K.M. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J. Control. Release 2003, 86:93-100.
162. Huynh L., Leroux J.C., Allen C. Enhancement of docetaxel solubility via conjugation of formulation-compatible moieties. Org. Biomol. Chem. 2009, 7:3437-3446.
163. Ali S., Ahmad I., Peters A., Masters G., Minchey S., Janoff A., Mayhew E. Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities. Anticancer Drugs 2001, 12:117-128.
164. Dhanikula A.B., Panchagnula R. Preparation and characterization of water-soluble prodrug, liposomes and micelles of Paclitaxel. Curr. Drug Deliv. 2005, 2:75-91.
165. Zhigaltsev I.V., Winters G., Srinivasulu M., Crawford J., Wong M., Amankwa L., Waterhouse D., Masin D., Webb M., Harasym N., Heller L., Bally M.B., Ciufolini M.A., Cullis P.R., Maurer N. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J. Control. Release 2010, 144:332-340.
166. Parness J., Kingston D.G., Powell R.G., Harracksingh C., Horwitz S.B. Structure-activity study of cytotoxicity and microtubule assembly in vitro by Taxol and related taxanes. Biochem. Biophys. Res. Commun. 1982, 105:1082-1089.
167. Zhu Q., Guo Z., Huang N., Wang M., Chu F. Comparative molecular field analysis of a series of paclitaxel analogues. J. Med. Chem. 1997, 40:4319-4328.
168. Kingston D.G. Recent advances in the chemistry of Taxol. J. Nat. Prod. 2000, 63:726-734.
169. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1615-1626.
170. Low P.S., Antony A.C. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv. Drug Deliv. Rev. 2004, 56:1055-1058.
171. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 2004, 56:1067-1084.
172. Wu J., Liu Q., Lee R.J. A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm. 2006, 316:148-153.
173. Liu Y., Li K., Pan J., Liu B., Feng S.S. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel. Biomaterials 2010, 31:330-338.
174. Xu Z., Chen L., Gu W., Gao Y., Lin L., Zhang Z., Xi Y., Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009, 30:226-232.
175. Ritter C.A., Arteaga C.L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 2003, 30:3-11.
176. Gao Y., Chen L., Gu W., Xi Y., Lin L., Li Y. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. Mol. Pharm. 2008, 5:1044-1054.
177. Moody T.W., Gozes I. Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr. Pharm. Des. 2007, 13:1099-1104.
178. Gespach C., Bawab W., de Cremoux P., Calvo F. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 1988, 48:5079-5083.
179. Rubinstein I., Soos I., Onyuksel H. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem. Biol. Interact. 2008, 171:190-194.
180. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 2008, 26:552-558.
181. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA 2007, 104:15549-15554.
182. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66:6732-6740.
183. Wu A.M., Yazaki P.J., Tsai S., Nguyen K., Anderson A.L., McCarthy D.W., Welch M.J., Shively J.E., Williams L.E., Raubitschek A.A., Wong J.Y., Toyokuni T., Phelps M.E., Gambhir S.S. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl. Acad. Sci. USA 2000, 97:8495-8500.
184. Hussain S., Pluckthun A., Allen T.M., Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule-targeted nanovesicular drug delivery system. Mol. Cancer Ther. 2007, 6:3019-3027.
185. Kircheis R., Wightman L., Schreiber A., Robitza B., Rossler V., Kursa M., Wagner E. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 2001, 8:28-40.
186. Muller R.H., Ruhl D., Runge S., SchulzeForster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
187. Muller R.H., Maassen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharmaceut. 1996, 138:85-94.
188. Fu K., Pack D.W., Klibanov A.M., Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 2000, 17:100-106.
189. Majoros I.J., Myc A., Thomas T., Mehta C.B., Baker J.R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7:572-579.
190. Lim J., Simanek E.E. Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups. Org. Lett. 2008, 10:201-204.
191. Ooya T., Lee J., Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjug. Chem. 2004, 15:1221-1229.
192. Lacko A.G., Nair M., Prokai L., McConathy W.J. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Exp. Opin. Drug Deliv. 2007, 4:665-675.
193. McConathy W.J., Nair M.P., Paranjape S., Mooberry L., Lacko A.G. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008, 19:183-188.
194. Masquelier M., Vitols S., Palsson M., Mars U., Larsson B.S., Peterson C.O. Low density lipoprotein as a carrier of cytostatics in cancer chemotherapy: study of stability of drug-carrier complexes in blood. J. Drug Target. 2000, 8:155-164.
195. Eisenberg S., Windmueller H.G., Levy R.I. Metabolic fate of rat and human lipoprotein apoproteins in the rat. J. Lipid Res. 1973, 14:446-458.
196. Ho Y.K., Smith R.G., Brown M.S., Goldstein J.L. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978, 52:1099-1114.
197. Fiorenza A.M., Branchi A., Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. 2000, 30:141-145.
198. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J. Drug Target. 2010, 18:53-58.
199. Yezhelyev M., Yacoub R., O'Regan R. Inorganic nanoparticles for predictive oncology of breast cancer. Nanomedicine (London) 2009, 4:83-103.
200. Lu J., Liong M., Sherman S., Xia T., Kovochich M., Nel A.E., Zink J.I., Tamanoi F. Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnology 2007, 3:89-95.
201. Paciotti G.F., Kingston D.G.I., Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug. Develop. Res. 2006, 67:47-54.
202. Hwu J.R., Lin Y.S., Josephrajan T., Hsu M.H., Cheng F.Y., Yeh C.S., Su W.C., Shieh D.B. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J. Am. Chem. Soc. 2009, 131:66-68.
203. Hua M.Y., Yang H.W., Chuang C.K., Tsai R.Y., Chen W.J., Chuang K.L., Chang Y.H., Chuang H.C., Pang S.T. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010, 31:7355-7363.
204. Gibson J.D., Khanal B.P., Zubarev E.R. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc. 2007, 129:11653-11661.
205. van Schooneveld M.M., Vucic E., Koole R., Zhou Y., Stocks J., Cormode D.P., Tang C.Y., Gordon R.E., Nicolay K., Meijerink A., Fayad Z.A., Mulder W.J. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 2008, 8:2517-2525.